丙酚替诺福韦在乙肝母婴阻断中的研究进展  

Research progress of tenofovir alafenamide in blocking mother-tochild transmission of hepatitis B virus

作　　者：戚林玲 刘寿荣 QI Linling;LIU Shourong(Zhejiang Chinese Medical University,Hangzhou 310020,Zhejiang,China;Department of Hepatology,Affiliated Hangzhou Xixi Hospital,Zhejiang University School of Medicine,Hangzhou 310023,Zhejiang,China)

机构地区：[1]浙江中医药大学,浙江杭州310020 [2]浙江大学医学院附属杭州市西溪医院肝病科,浙江杭州310023

出　　处：《中国临床药理学与治疗学》2023年第5期578-582,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：浙江省医药卫生科研面上项目(2018KY628);杭州市农业与社会发展科研重点专项(202204A02)。

摘　　要：乙型肝炎病毒感染是一个全球公共卫生问题,预防母婴传播是其重要干预方法,丙酚替诺福韦作为一种新型核苷类逆转录酶抑制药,具有肝脏靶向性强、外周血暴露量低的特点,已被广泛应用于乙型病毒性肝炎的治疗中,而在乙肝母婴阻断中的应用仍有限。本文就丙酚替诺福韦的特点,丙酚替诺福韦对婴幼儿和孕妇的影响方面进行综述,以期为预防乙肝母婴传播提供新思路。Hepatitis B virus(HBV)infection is a global public health problem,and the prevention of mother-to-child transmission(MTCT)is an im-portant intervention method.As a new nucleoside reverse transcriptase inhibitor,tenofovir alafen-amide(TAF)has the characteristics of strong liver targeting and low peripheral blood exposure.Al-though it has been used in the treatment of chron-ic hepatitis B widely,its application in blocking mother-to-child transmission of HBV is still limited.This paper reviews the characteristics of TAF,the ef-fects of TAF on infants and pregnant women,in or-der to provide new ideas for the prevention of mother-to-child transmission of HBV.

关 键 词：丙酚替诺福韦 乙型病毒性肝炎 母婴阻断 

分 类 号：R512.6[医药卫生—内科学]